# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2016 Earnings Results

**Report date:** 2016-08-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2016

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.81%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.82 | N/A | +63.48% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's product pipeline. They emphasized their commitment to innovation despite market challenges.

**Key quotes:**

> Management highlighted the strong performance in their key product lines.

> They noted ongoing investments in research and development to drive future growth.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's earnings report showed a significant beat on EPS, indicating strong profitability. However, the stock reacted negatively, declining by 1.81%. This could suggest that investors were looking for more comprehensive revenue details or future guidance, which were not provided.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2016_